Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in B-cell Lymphoma: From Diagnostics to Cure
share announcement

Advances in B-cell Lymphoma: From Diagnostics to Cure

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 June 2025 | Viewed by 2474

Special Issue Editors

Prof. Dr. Leo I. Gordon

E-Mail Website
Guest Editor
Hematology Oncology Division, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Interests: lymphoma; hodgkin's lymphoma; therapy
Special Issues, Collections and Topics in MDPI journals
Dr. Megan E. Melody

E-Mail Website
Guest Editor
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Interests: B-cell lymphoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

We are pleased to announce the call for submissions to a Special Issue of the journal Cancers, focusing on the topic of advances in B-cell lymphoma. Non-Hodgkin, B-cell lymphomas rank as the tenth most common cancer worldwide, accounting for >60% of all hematopoietic neoplasms. Over the past decade, significant advances have been made regarding the classification, prognostication and treatment of B-cell lymphomas, raising questions about how to best optimize the management of this heterogenous disease. 

This Special Issue aims to provide a comprehensive overview of the current knowledge and advancements in B-cell lymphoma, from its underlying pathology to innovative treatment strategies. We invite the submission of original research articles and reviews that cover various aspects of the management of B-cell lymphoma, including, but not limited to: 

  1. Molecular and genetic profiling of B-cell lymphoma;
  2. Novel biomarkers, prognostic markers and markers of minimal residual disease;
  3. Insights into the tumor microenvironment and immune response;
  4. Targeted therapies and immunotherapies for B-cell lymphoma;
  5. Advances in cellular therapies. 

All submitted articles will undergo a rigorous peer review process to ensure the highest scientific quality and relevance to the field. We encourage contributions from researchers, clinicians and experts in the field of hematopathology, lymphoma research and cellular therapy. 

By consolidating the latest research findings and clinical experiences, we aim to enhance our understanding of the newest advances in lymphoma diagnosis, classification, prognostication and management. We believe that your valuable contributions will significantly contribute to the success of this Special Issue. 

Should you have any questions, require further information or need any assistance, please do not hesitate to reach out to us. 

We look forward to receiving your valuable submissions. 

Prof. Dr. Leo I. Gordon
Dr. Megan E. Melody
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • B-cell lymphoma
  • treatment
  • molecular profiling
  • immunotherapies
  • cellular therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 2400 KiB  
Article
Prognostic Significance of Interim PET/CT in the First-Line Treatment of Follicular Lymphoma Patients, a Single-Center Experience
by Evelin Kiss, Zsófia Simon, Árpád Illés and Ádám Jóna
Cancers 2025, 17(1), 73; https://doi.org/10.3390/cancers17010073 - 29 Dec 2024
Viewed by 1245
Abstract
Introduction: Follicular lymphoma (FL) is a heterogeneous disease, and identifying high-risk patients early is crucial for optimal management. This study aimed to evaluate the prognostic significance of interim positron emission tomography/computed tomography (PET/CT) in newly diagnosed FL patients undergoing first-line treatment. Methods [...] Read more.
Introduction: Follicular lymphoma (FL) is a heterogeneous disease, and identifying high-risk patients early is crucial for optimal management. This study aimed to evaluate the prognostic significance of interim positron emission tomography/computed tomography (PET/CT) in newly diagnosed FL patients undergoing first-line treatment. Methods: This single-center, retrospective study included 103 patients with newly diagnosed FL who underwent interim PET/CT. The primary endpoint was progression-free survival (PFS). The prognostic value of positive interim PET/CT, Deauville scores, and maximum standardized uptake values (SUVmax) were analyzed among other clinical features. Results: A total of 30 patients (29.1%) were deemed interim PET/CT-positive. The interim PET/CT-positive group demonstrated a significantly shorter median PFS compared to the interim PET/CT-negative group (17 months vs. not reached, respectively; p < 0.0001). Similarly, patients with Deauville scores of 1–3 had better PFS, with median survival not yet reached, while those with higher Deauville scores exhibited poorer progression-free survival and a median survival of 18 months. Notably, patients with an interim PET/CT SUVmax exceeding 3.365 experienced significantly shorter median survival compared to those with lower values. Discussion: Our findings support the use of interim PET/CT as a prognostic tool in FL. These results are consistent with other studies, although some debate exists regarding the optimal PET/CT metric. Further research is needed to validate these findings and explore personalized treatment strategies based on interim PET/CT results. Full article
(This article belongs to the Special Issue Advances in B-cell Lymphoma: From Diagnostics to Cure)
►▼ Show Figures

Figure 1

Other

Jump to: Research

9 pages, 920 KiB  
Commentary
Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing
by Daniel J. Landsburg
Cancers 2025, 17(1), 18; https://doi.org/10.3390/cancers17010018 - 24 Dec 2024
Cited by 1 | Viewed by 719
Abstract
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) and high-grade B cell lymphoma (HGBL) comprise the majority of large B-cell lymphomas (LBCL), and approximately two-thirds of patients diagnosed with these LBCLs are cured following treatment with first-line immunochemotherapy. While the International Prognostic Index (IPI) score [...] Read more.
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) and high-grade B cell lymphoma (HGBL) comprise the majority of large B-cell lymphomas (LBCL), and approximately two-thirds of patients diagnosed with these LBCLs are cured following treatment with first-line immunochemotherapy. While the International Prognostic Index (IPI) score is a validated prognostic tool used for patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), there is a growing body of evidence that suggests that LBCL tumor features, which can be detected by clinical laboratory testing, can predict patient survival following first-line immunochemotherapy. Conclusions: Clinical laboratory testing may also allow for rational identification of targeted agents that can be added to first-line immunochemotherapy for high-risk, pathologically defined subsets of LBCL patients, and this approach may result in better survival outcomes for the entire LBCL patient population as compared with adding pathologically “agnostic” agents for those defined as high risk by IPI score. Full article
(This article belongs to the Special Issue Advances in B-cell Lymphoma: From Diagnostics to Cure)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop